Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1969 1
1970 1
1990 1
1993 1
1998 2
2003 1
2008 1
2009 1
2010 1
2012 1
2013 4
2014 6
2015 5
2016 7
2017 3
2018 7
2019 8
2020 9
2021 13
2022 35
2023 22
2024 20
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment.
Rybak YE, Lai KSP, Ramasubbu R, Vila-Rodriguez F, Blumberger DM, Chan P, Delva N, Giacobbe P, Gosselin C, Kennedy SH, Iskandar H, McInerney S, Ravitz P, Sharma V, Zaretsky A, Burhan AM. Rybak YE, et al. Among authors: burhan am. Depress Anxiety. 2021 Apr;38(4):456-467. doi: 10.1002/da.23135. Epub 2021 Feb 2. Depress Anxiety. 2021. PMID: 33528865 Free PMC article. Review.
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Porsteinsson AP, et al. JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93. JAMA. 2014. PMID: 24549548 Free PMC article. Clinical Trial.
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.
Smith EE, Phillips NA, Feldman HH, Borrie M, Ganesh A, Henri-Bhargava A, Desmarais P, Frank A, Badhwar A, Barlow L, Bartha R, Best S, Bethell J, Bhangu J, Black SE, Bocti C, Bronskill SE, Burhan AM, Calon F, Camicioli R, Campbell B, Collins DL, Dadar M, DeMarco ML, Ducharme S, Duchesne S, Einstein G, Fisk JD, Gawryluk JR, Grossman L, Ismail Z, Itzhak I, Joshi M, Harrison A, Kröger E, Kumar S, Laforce R, Lanctot KL, Lau M, Lee L, Masellis M, Massoud F, Mitchell SB, Montero-Odasso M, Myers Barnett K, Nygaard HB, Pasternak SH, Peters J, Rajah MN, Robillard JM, Rockwood K, Rosa-Neto P, Seitz DP, Soucy JP, Trenaman SC, Wellington CL, Zadem A, Chertkow H; Canadian Consortium on Neurodegeneration in Aging Investigators. Smith EE, et al. Among authors: burhan am. J Prev Alzheimers Dis. 2025 Mar;12(3):100068. doi: 10.1016/j.tjpad.2025.100068. Epub 2025 Jan 31. J Prev Alzheimers Dis. 2025. PMID: 39893139 Free PMC article. Review.
159 results